Browse

Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model

Cited 39 time in Web of Science Cited 46 time in Scopus
Authors
Ugur, Hasan C; Ramakrishna, Naren; Bello, Lorenzo; Menon, Lata G; Kim, Seung-Ki; Black, Peter M; Carroll, Rona S
Issue Date
2007-02-21
Publisher
Springer Verlag
Citation
J Neurooncol. 2007 Jul;83(3):267-75. Epub 2007 Feb 20.
Keywords
AnimalsAntineoplastic Agents/*administration & dosage/pharmacologyBrain Neoplasms/blood supply/*drug therapy/enzymologyCell Proliferation/drug effectsFlow CytometryGene Expression Regulation, NeoplasticGlioma/blood supply/*drug therapy/enzymologyHistone Deacetylases/antagonists & inhibitorsHumansHydroxamic Acids/*administration & dosage/pharmacologyInfusion Pumps, ImplantableMaleMiceMice, NudeNeovascularization, PathologicSurvival RateTumor Cells, Cultured/transplantationXenograft Model Antitumor Assays
Abstract
OBJECT: Current treatments for malignant gliomas produce only a modest increase in survival time. New therapeutic approaches are desperately needed. Suberoylanilide hydroxamic acid (SAHA) is an effective inhibitor of the growth of many solid and hematological malignancies. Nevertheless, very few studies have investigated the effects of SAHA on glial tumors. The present study was designed to investigate the therapeutic effects of the intracranial local delivery of SAHA in an orthotopic glioma model. METHODS: The antiproliferative effect of SAHA was examined in six glioblastoma and one endothelial cell lines in vitro. In addition, one glioblastoma cell line (U87MG) used in in vivo short term (14 days) and survival studies in an orthotopic human glioma athymic mice model. Tumor volume, apoptosis rate, microvessel density, and proliferation index were determined by immunohistochemistry. RESULTS: SAHA treatment inhibited the growth of all cell lines in concentrations ranging from 1 microM to 30 microM. For short-term studies, histological analysis showed an 80% reduction of tumor volume in the treatment group (P < 0.001). This reduction in tumor volume was associated with a significant increase in the apoptosis rate (31.9%, P < 0.001), a significant decrease in the proliferation (36.8%, P < 0.001) and angiogenesis rates (30%, P < 0.05). For survival studies, the mean survival time was 22 days in the control group, whereas it was 42 days in the treatment group. CONCLUSIONS: These results suggest that local delivery with SAHA inhibits intracranial glioma growth in vitro and in vivo. SAHA is a promising candidate for further preclinical and clinical studies on glial tumors.
ISSN
0167-594X (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17310267

http://hdl.handle.net/10371/15498
DOI
https://doi.org/10.1007/s11060-007-9337-z
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Neurosurgery (신경외과학전공)Journal Papers (저널논문_신경외과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse